A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladder sparing curative treatment for muscle invasive bladder cancer: the CRIMI study

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Amsterdam UMC

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

11 Oct 2024 → ongoing

Decision date (initial)

2024-10-11

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Bristol-Myers Squibb

External identifiers

EU CT number

2023-509460-19-00

EudraCT number

2017-004751-23

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Dose response

*to assess toxicity
*to assess the feasibility and safety of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder.
*to assess the feasibility , the disease free survival (DFS) and disease free survival rate (DFS-rate) of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder

Secondary objectives 6

1. to assess overall survival
2. to assess overal survival-rate
3. to assess response rate
4. To investigate the association between biomarkers in the peripheral blood and tumor tissue and auto-immune adverse events.
5. To investigate the association between biomarkers and treatment efficacy
6. to assess toxicity

Conditions and MedDRA coding

Muscle Invasive bladder cancer

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 14

1. Be willing and able to provide written informed consent for the trial.
2. Be ≥ 18 years of age on day of signing informed consent.
3. Wish to preserve their bladder function or be ineligible for cystectomy.
4. Must have undergone transurethral biopsy of the bladder tumor, within 35 days of planned treatment commencement. The patient should have a histologically-confirmed diagnosis of muscle-invasive T2-T4a, N0-1M0 urothelial cell carcinoma of the bladder.
5. Must have undergone maximal transurethral resection of the bladder tumour, to an extent that is judged as safe by the urologist performing the resection, within 35 days of planned treatment commencement.
6. Subjects with tumors of mixed urothelial/non-urothelial cell histology are allowed, but urothelial cell carcinoma must be the predominant histology (>50%). Subjects with predominant or exclusively non-urothelial cell histology are not allowed.
7. Have planned for chemoradiotherapy as definitive treatment.
8. Have a performance status of 0 or 1 on the ECOG Performance Scale
9. Have a bladder function that is accessible for cystoscopic follow up.
10. Demonstrate adequate organ function as defined below. All screening labs should be performed within 28 days of registering the patient on the trial. Screening laboratory values must meet the following criteria: - WBCs ≥ 2000/μL - Neutrophils ≥ 1500/μL - Platelets ≥ 100 x 10³/μL - Hemoglobin ≥ 5.5 mmol/l - creatinine clearance (CrCl) ≥ 40 mL/minute (using Cockcroft/Gault formula or better) - AST ≤ 3 x ULN vii) ALT ≤ 3 x ULN - Total Bilirubin ≤ 1.5 x ULN (except for subjects with Gilbert Syndrome a total bilirubin ≤ 50 umol/L) - Albumin ≥ 30 mg/L - Lipase ≤ 1.5 ULN. Subjects with Lipase ≥ 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis. - Amylase ≤ 1.5 ULN. Subjects with Amylase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis.
11. Female participants of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registering the patient. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
12. Female participants of childbearing potential should be willing to one highly effective method of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 month after the last dose of study medication Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
13. Male participants should agree to use condoms starting with the first dose of study therapy through 7 month after the last dose of study therapy.
14. Willing to consent to the use of their collected tumor specimen, blood and urine as detailed in the protocol for future scientific research including but not limited to DNA, RNA and protein based biomarker detection.

Exclusion criteria 23

1. Has DPD deficiency
2. Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) urothelial cell carcinoma of the urothelium. Patients who have involvement of the prostatic urethra with urothelial cell cancer may be included if the location can be safely incorporated in the radiation field.
3. Extensive or multifocal bladder carcinoma in situ (CIS) precluding curative chemoradiotherapy.
4. Evidence of distant metastatic disease on a CT or FDG PET/CT chest/abdomen/pelvis performed within 28 days prior to study entry. Up to 3 metastatic lymph nodes in the pelvis (below the common iliac arteries) are allowed, if these can be incorporated in the radiotherapy field.
5. Prior pelvic lymphadenectomy
6. Prior pelvic radiotherapy
7. Has had prior intravenous chemotherapy, targeted small molecule therapy, or radiation therapy for treatment of bladder cancer. Prior intravesical BCG and MMC is permitted.
8. Unsuitable for concurrent MMC / capecitabine based ChRT based on pre-existing medical conditions.
9. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment. An exception is fiducials that are aimed at improving positional stability during the radiotherapy treatment course. These are allowed.
10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy over 10mg daily prednisone (or equivalent) or any other form of immunosuppressive therapy within 14 days prior to registering the patient. Patients with adrenal insufficiency receiving replacement dose steroids are allowed on the trial.
11. Has a known history of active TB (Bacillus Tuberculosis)
12. Hypersensitivity to nivolumab and/or ipilimumab or any of its excipients.
13. Prior or concurrent known additional malignancy of any site unless disease free for 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, Stage T1a well differentiated prostatic carcinoma in men (Gleason = 3+3, PSA <5)
14. Has any history of active autoimmune disease, Stevens-Johnson syndrome or Guillain-Barre. Exceptions to this are: a. Patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone b. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen
15. Has known history of, or any evidence of active, non-infectious pneumonitis.
16. Has an active infection requiring systemic therapy.
17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
18. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
19. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
20. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
21. Has an Human Immunodeficiency Virus (HIV) infection with a PCR detectable viral load.
22. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
23. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. In the phase Ib study: toxicity scored with CTCAE v 4.03; incidence of dose limiting toxicity (DLT) during the first 6 weeks after start of the combination
2. In the phase II study: disease free survival (DFS) and disease free survival-rate (DFS-rate)

Secondary endpoints 4

1. Overall Survival
2. Overall survival-rate
3. Response rate according to RECIST 1.1
4. Toxicity according to CTCAE v4.03

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 4

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Amsterdam UMC

Sponsor organisation

Amsterdam UMC

Address

De Boelelaan 1117

City

Amsterdam

Postcode

1081 HV

Country

Netherlands

Scientific contact point

Organisation

Amsterdam UMC

Contact name

Marc Zuurbier

Public contact point

Organisation

Amsterdam UMC

Contact name

Marc Zuurbier

Locations

1 EU/EEA country · 2 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 11 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications